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Introduction
Breast cancer (BC) is the most common malignancy 
diagnosed in women (Jemal et al., 2011; Bray et al., 2013). 
It is also the most frequent cancer in young women of 
reproductive age and comprises approximately 40% of 
all female cancers in this age group ( Jemal et al., 2009). 
Nearly 2% of BC is diagnosed in young women between 
20 and 34 years of age, and 11% between 35 and 44 
years of age ( Rodriguez-Wallberg and Oktay, 2010). The 
incidence of breast cancer in young women of reproductive 
age has been increasing in recent decades (Leclere et al., 
2013; Keramatinia et al., 2014). Early diagnosis, adjuvant 
therapy, and higher cure rates have resulted in longer 
survival and lower mortality. It is estimated that a 50% 
increase in the number of patients diagnosed with cancer 
will occur by 2030. Currently, the five-year survival rate 
for BC is >90% in developed countries. BC survivors 
are a major part of cancer survivors in many countries. 
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Abstract
 Background: Since the survival rate of breast cancer patients has improved, harmful effects of new treatment 
modalities on fertility of the young breast cancer patients has become a focus of attention. This study aimed to 
systematically review and critically appraise all available guidelines for fertility preservation in young breast 
cancer patients. Materials and Methods: Major citation databases were searched for treatment guidelines. Experts 
from relevant disciplines appraised the available guidelines. The AGREE II Instrument that includes 23 criteria 
in seven domains (scope and purpose of the guidelines, stakeholder involvement, rigor of development, clarity, 
applicability, editorial independence, and overall quality) was used to apprise and score the guidelines. Results: 
The search strategy retrieved 2,606 citations; 72 were considered for full-text screening and seven guidelines were 
included in the study. There was variability in the scores assigned to different domains among the guidelines. 
ASCO (2013), with an overall score of 68.0%, had the highest score, and St Gallen, with an overall score of 
24.7%, had the lowest scores among the guidelines. Conclusions: With the promising survival rate among breast 
cancer patients, more attention should be given to include specific fertility preservation recommendations for 
young breast cancer patients. 
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Young women with breast cancer are faced with many 
undesired consequences of cancer therapies, such as long 
duration of treatment, psychosocial problems, infertility, 
sexual dysfunction, and even occurrence of other cancers. 
For these reasons, quality of life remains an important 
consideration for patients surviving BC, particularly those 
<40 years of age, and interdisciplinary collaboration has 
become an essential part of survivor management. Among 
various side effects of BC, the issues of fertility have 
been recognized with great importance for young women 
diagnosed with breast cancer (Sonmezer and Oktay, 
2004; Ewertz and Jensen, 2010; Rodriguez-Wallberg and 
Oktay, 2010; Christinat and Pagani, 2012; Husseinzadeh 
and Husseinzadeh, 2013; Lange et al., 2013). After the 
publication of first guidelines on fertility preservation 
(FP) for cancer patients by American Society of Clinical 
Oncology (ASCO) in 2006 (Lee et al., 2006), and National 
Institute for Health and Clinical Excellence (NICE) 
in 2004 (National Collaborating Center for Women’s 
Mahnaz Haddadi et al
Asian Pacific Journal of Cancer Prevention, Vol 16, 20151058
and Children’s Health (UK), 2004), oncologists are 
recommended to discuss the influences of cancer therapies 
on fertility with their young patients as early as possible 
and consider fertility preservation as a part of care. Both 
of these guidelines were updated recently (Fields et al., 
2013; Loren et al., 2013). As a result of considerable 
improvement in assisted reproductive technology (ART), 
nowadays there are several options to restore fertility 
in young women including cryopreservation of oocyte, 
embryo and ovarian tissue, and in vitro maturation of 
oocyte before starting cancer treatment. Except embryo 
freezing, most of these techniques were investigational 
during the release of the first ASCO and NICE guidelines. 
Cryopreservation of ovarian tissue seems to be a promising 
method of preserving fertility in the young breast cancer 
patients (YBCP). This method is also so important for 
the patient`s physiology that can avoid menopausal 
symptoms. Ovarian freezing as the emerging discipline 
of assisted reproductive technologies is progressively 
attracting interest to preserve fertility for young cancer 
patients. Fertility preservation options have also been 
used for other diseases such as lupus, glomerulonephritis, 
myelodysplasia, and premature ovarian failure as well as 
in women who wish to preserve their ovarian function for 
future reproductive potential and delayed childbearing 
age (Posada et al., 2001; Imhof et al., 2004; Demeestere 
et al., 2007; Maltaris et al., 2007; Isachenko et al., 2007; 
Ajala et al., 2010; Rahimi et al., 2010; Dolmans et al., 
2010; Michaeli et al., 2012; Husseinzadeh, 2013). Despite 
rapid progress in cryopreservation technology and existing 
other resources and infrastructure, fertility preservation 
for young breast cancer patients is in its early stage with 
many challenges 
(Posada et al., 2001; Imhof et al., 2004; National 
Collaborating Center for Women’s and Children’s Health 
(UK), 2004; Sonmezer and Oktay, 2004; Lee et al., 2006; 
Demeestere et al., 2007; Isachenko et al., 2007; Maltaris 
et al., 2007; Ajala et al., 2010; Dolmans et al., 2010; 
Ewertz and Jensen, 2010; Rahimi et al., 2010; Christinat 
and Pagani, 2012; Klemp and Kim, 2012; King et al., 
2012; Michaeli et al., 2012; Klemp and Kim, 2012; King 
et al., 2012; Fields et al., 2013; Husseinzadeh, 2013; 
Husseinzadeh and Husseinzadeh, 2013; Lange et al., 2013; 
Leclere et al., 2013; Loren et al., 2013; Ronn and Holzer, 
2013). The present study aimed to systematically review 
available guidelines on preservation of fertility in breast 
cancer patients.
Materials and Methods
Systematic literature search
A systematic literature search for existing guidelines of 
FP in patients with BC was performed using MEDLINE and 
Google Scholar databases. The search strategy comprised 
three main components: guidelines in any terms, breast 
cancer in appropriate terms, and fertility preservation 
in any possible terms (Appendix 1). In addition, eight 
Guideline Websites were searched including National 
Guideline Clearing House (http://www.guideline.gov/), 
National Comprehensive Cancer Network (http://www.
nccn.org/professionals/physician_gls/f_guidelines.asp), 
The Scottish Intercollegiate Guidelines Network (http://
www.sign.ac.uk/), The Canadian Medical Association 
InfoBase for Clinical Practice Guidelines (http://www.
cma.ca/cpgs/), Guidelines International Networks 
(http://www.g-i-n.net/), American College of Physicians 
Clinical Practice Guidelines (http://www.acponline.
org/clinical_information/guidelines/guidelines/), NICE 
(http://www.nice.org.uk/), and Fertile Hope (http://www.
fertilehope.org). Searches were limited to papers published 
in English language from December 2003 to December 
2013. Guidelines to fertility preservation in patients with 
breast cancer were included using consensus or evidence-
based strategies. The latest version was included if the 
guidelines had been updated. 
Quality and content evaluation
The guideline appraisal group comprised four experts 
from disciplines of medical oncology, epidemiology, 
cancer surgery, and assisted-reproductive technology. The 
quality of guidelines was assessed by AGREE II Instrument 
(AGREE Collaboration, 2003),1 in which 23 criteria in 
seven domains were evaluated. These include the scope 
and purpose of the guidelines, stakeholder involvement, 
and rigor of development, clarity, applicability, editorial 
independence, and overall quality. Each appraiser scored 
the guidelines independently, and results were gathered 
and analyzed by other investigators who did not participate 
in the assessment. The appraisers’ scores were expressed 
as standardized domain scores on a percentage scale 
(0%-100%).
Results 
The search strategy retrieved 2606 citations; 72 were 
considered for full-text screening, and seven guidelines 
(Goldhirsch et al., 2009; Von Wolff et al., 2011; Cardoso 
et al., 2012; Coccia et al., 2012; ISFP Practice Committee 
et al., 2012; Klemp and Kim, 2012; Loren et al., 2013) 
were included in the study (Figure 1). 
The guidelines included were from the American 
Society of Clinical Oncology (ASCO 2013), European 
Society of Breast Cancer Specialists (EUSOMA 2012), 
International Society for Fertility Preservation (ISFP, 
May, 22 and 31 2012), National Comprehensive Cancer 
Network (NCCN 2012), FertiPROTEKT (2011), and St 
Gallen International Expert Consensus (2009). The ASCO 
Figure 1. Quorum Diagram
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guideline was an updated version; the rest were new. ISFP 
provided two guidelines; one guideline was specifically 
related to breast cancer patients’ fertility preservation. 
There was variability in the scores assigned to different 
domains between the guidelines. Among the different 
domains, the rigor of development had the lowest scores for 
all the guidelines compared with the other domains. ASCO 
(2013), with an overall score of 68.0%, had the highest 
score, and St Gallen, with an overall score of 24.7%, had 
the lowest scores among the guidelines. In the domain of 
scope and purpose, there were similarities in assigning 
scores to different guidelines, except St Gallen that scored 
very low (a score of 25.0%). ASCO received the highest 
score (91.7%) in the domain of stakeholder involvement, 
whereas the majority of guidelines performed <50% in 
this domain. Many of the guidelines received scores of 
>50% in clarity of presentation, except St. Gallen, with 
a low score of 30.1%. Except for ASCO that scored high 
(71.9%), other guidelines scored <50% in the applicability 
domain. In the editorial independency domain, EUSOMA 
had a score of 37.5% and St. Gallen had a score of 12.5%, 
whereas other guidelines had scores >50%. The ASCO and 
NCCN guidelines described the guideline development 
process and stakeholder involvement in detail, whereas 
the remaining guidelines provided some brief description 
without details of stakeholder involvement. With the 
exception of ASCO, none of the guidelines reported a 
systematic search strategy in their methodology section. 
The detailed AGREE II appraisal results are presented 
at Table 1. 
Only one guideline (ISFP) was exclusively devoted to 
fertility preservation for young patients with breast cancer, 
whereas the others recommend fertility preservation for 
other cancers. Seven fertility preservation procedures 
recommended for patients were identified across the 
guidelines (Table 2). Embryo freezing, mature oocyte 
cryopreservation and ovarian tissue freezing were 
recommended by all the guidelines. Ovarian suppression 
using GnRH agonists before chemotherapy were advised 
by six guidelines (Table 2). Donor eggs, surrogacy, and 
adoption were proposed only by ASCO. 
Discussion
Our study systematically reviewed fertility preservation 
using major guidelines. The importance of fertility 
preservation in young breast cancer patients was assessed 
in the major practicing and currently used guidelines. All 
the evaluated guidelines had recommendations on fertility 
preservation for cancer patients undergoing chemotherapy 
or other treatment modalities with a high risk of infertility. 
It is obvious that fertility preservation is an important 
issue for reproductive-age breast cancer patients. ASCO, 
NICE, American Society for Reproductive Medicine, and 
other important organizations recommend that oncology 
centers should offer fertility counseling to their patients 
(Goldhirsch, et al., 2009; Pentheroudakis, et al., 2010; Von 
Wolff, et al., 2011;Klemp and Kim, 2012; Cardoso, et al., 
2012; ISFP Practice Committee1, et al., 2012; Fields, et 
al., 2013; Loren, et al., 2013). Young women represent a 
relatively small proportion of breast cancer patients and 
their options for fertility preservation have been limited 
by many factors such as safety, efficacy issues, and 
inadequate time before starting cancer therapies. These 
women experience strong psychosocial distress and also 
face long-term impairments in their quality of life and 
fertility. Additionally, the problems of young patients 
affect some of their relatives, and more people come 
to bear the breast cancer burden (Sonmezer and Oktay, 
2004; Cruz et al., 2010; ISFP Practice Committee1 et al., 
2012;). Studies has reported gaps in young cancer patients 
receiving fertility counseling even in the developed 
Table 1. AGREE II Domain Scores for Fertility Preservation Guidelines in Patients with Breast Cancer
Organization [Year] Scope and  Stakeholder  Rigor of  Clarity of  Applicability % Editorial  Overall 
 purpose % involvement % development % presentation %  independence % score %
ASCO14[2013] 69.4 91.7 62.5 50 71.9 62.5 68
EUSOMA30[2012] 45.8 63.8 44.8 62.5 17.7 37.5 45.4
ISFP26[2012, specific] 79.3 30.6 13 73.6 42.7 50 48.2
ISFP31[2012, general] 45.8 48.6 6.3 79.2 15.6 50 42
NCCN32[2012] 47.2 44.4 25 65.3 26 50 45.1
FertiPROTEKT33[2011] 55.6 61.1 40.6 91.6 44.8 50 57.3
St Gallen34[2009] 25 43.1 18.8 30.1 18.8 12.5 24.7
Mean score 52.6 54.8 30.1 64.6 33.9 44.6 47.2
Notes: ASCO=American Society of Clinical Oncology; EUSOMA=European Society of Breast Cancer Specialists; ISFP=International Society for 
Fertility Preservation; NCCN=National Comprehensive Cancer Network
Table 2.  Fertility Preservation Measures Recommended by Guidelines
 Embryo  Egg  Ovarian tissue  Ovarian  Donor eggs Surrogacy Adoption
 freezing freezing freezing suppression   
ASCO14[2013] 3 3 3 3 3 3 3
EUSOMA30[2012] 3 3 3 3 × × ×
ISFP26[2012, specific] 3 3 3 3 × × ×
ISFP31[2012, general] 3 3 3 3 × × ×
NCCN32[2012] 3 3 3 3 × × ×
FertiPROTEKT33[2011] 3 3 3 3 × × ×
St Gallen34[2009] 3 3 3 × × × ×
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countries for a simple reason that a young age at diagnosis 
reserve enough in future reproductive time ( Ronn and 
Holzer, 2013; Reinecke, 2013). It is estimated that even 
at the best and most favorable scenario, undergoing anti-
hormonal treatment alone can delay pregnancy for at 
least 5 years. Chemotherapy may cause severe follicle 
depletion, resulting in a loss of ≥10 years in reproductive 
function. Conversely, progressive neoadjuvant therapy 
before surgery is completed in some of these patients 
with clinically positive nodes or larger tumor size (>2 
cm). Neoadjuvant therapy impairs fertility as well as 
limits the fertility preservation options. Most cases of 
invasive BC occur between 30 and 40 years of age, 
shedding light on the critical role of age in diagnoses 
for desirable fertility preservation. In healthy females, 
after the age of 37–38 years, >90% of oocytes present 
at birth have already undergone atresia. Therefore, there 
are differences between the characterization of a young 
woman in oncology and gynecology (Kim et al., 2011; 
Lobo, 2005; Peccatori et al., 2012). The age-related 
fertility preservation options are not completely clear 
in current guidelines for oncologists, and may be very 
important because the value of early fertility preservation 
counseling for young cancer patient fully depends on it. 
Rapid counseling may allow YBCP sufficient time for 
one or two rounds of egg collection without delaying 
the start of their cancer treatmeKim et al., 2011). Some 
investigators have reported that the benefit of GnRH 
agonist therapy to protection of ovaries is unproven and 
it should not be offered as individual method of fertility 
preservation in young breast cancer patient (Sonmezer 
and Oktay, 2006; Bedoschi et al., 2013). Recent studies 
suggest that GnRH with chemotherapy in premenopausal 
women is associated with higher rates of resumption of 
menses, although it is not associated with improvement in 
pregnancy rates. Usage of less gonadotoxic regimens for 
adjuvant or neoadjuvant chemotherapy is a good choice 
and may be considered in YBCP with favorable tumors 
characteristic (Lobo, 2005; Kim et al., 2011). When 
cryopreservation of embryos or oocytes is not possible, 
ovarian tissue cryopreservation can be considered without 
a delay in cancer treatment (Oktay et al., 2003; 2005; 
Dolmans et al., 2010; Rahimi et al., 2010; Kim et al., 
2011; ISFP Practice Committee et al., 2012; Husseinzadeh, 
2013). Although many scientific or technical aspects of 
fertility preservation options are presented in current 
recommendations and guidelines, this matter raises 
several important ethical and legal issues that should be 
adequately addressed to young patients or parents before 
such techniques are used. Any decision must be in the 
patient’s preference and best interest. A very informed 
consent to accept any fertility preservation options is both 
a legal and an ethical need that must take consideration 
in practice ( Ethics Committee of the American Society 
for Reproductive Medicine, 2005; Wallace et al., 2005; 
Jeruss and Woodruff, 2009; Klock et al., 2010). Fertility 
preservation in cancer patients is an interdisciplinary 
approach. It needs the simultaneous functions of many 
components, which is a challenge. Many studies have 
shown that the most important weak points are poor access 
and referral to fertility services, low level of knowledge, 
and lack of available education for patients and health care 
providers (Forman et al., 2010; Klemp and Kim, 2012; 
King et al., 2012; Ronn and Holzer, 2013; Peate et al., 2013; 
Lange et al., 2013). Fertility preservation in breast cancer 
patients is even more complicated in underdeveloped 
countries with unsatisfactory health care infrastructure. 
Breast cancer survivors are one of the largest portion of 
cancer survivors (Dizon, 2009). Our results and many 
other reports demonstrate that comprehensive, specific, 
and practical guidelines for young breast cancer patients’ 
fertility preservation are rare (Ethics Committee of the 
American Society for Reproductive Medicine, 2005; 
Von Wolff et al., 2011). The lack of a suitable guideline 
that covers all aspects of fertility preservation in young 
patients with breast cancer is evident. An appropriate 
guideline for YBCP needs to offer fertility preservation 
options, considering costs, practicality, social values, and 
ethical consequences. Such a guideline should consider 
establishment of a multidisciplinary approach, providing 
effective engagement between oncologists, fertility 
specialists, and patients. Fertility preservation should be 
routinely started as early as possible after the diagnosis 
of breast cancer. Such a system also helps to decrease the 
pressure of decision making for both the patient and the 
oncologist.
In conclusion, in this study, we retrieved seven 
guidelines of fertility preservation for breast cancer 
patients. Critical appraisal of the present guidelines 
indicates that these guidelines do not appropriately address 
all aspects of a comprehensive guideline development. Not 
all available guidelines address specific recommendations 
for fertility preservation in young breast cancer patients. 
With the promising survival rate among breast cancer 
patients, more attention should be given to specific 
fertility preservation recommendations in young breast 
cancer patients.
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